

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sincere Pharmaceutical Group Limited
先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON NOVEMBER 1, 2021**

Reference is made to the notice (the “**EGM Notice**”) of the extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of Sincere Pharmaceutical Group Limited (the “**Company**”), both dated October 12, 2021. Unless the context requires otherwise, terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the EGM was held at No. 699-18, Xuanwu Road, Xuanwu District, Nanjing, Jiangsu, PRC on Monday, November 1, 2021 at 9:00 a.m., and the proposed resolutions as set out in the EGM Notice (the “**Resolution(s)**”) were duly passed by the Shareholders by way of poll. The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To approve and confirm the proposed grant of 2,025,000 RSUs to Mr. Wan Yushan pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
2.	To approve and confirm the proposed grant of 3,000,000 RSUs to Mr. Tang Renhong pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
3.	To approve and confirm the proposed grant of 411,000 RSUs to Mr. Shi Ruiwen pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
4.	To approve and confirm the proposed grant of 615,000 RSUs to Mr. Cheng Xianghua pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
5.	To approve and confirm the proposed grant of 615,000 RSUs to Mr. Lu Jianxue pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%

Ordinary Resolutions		Number of Votes (%)	
		For	Against
6.	To approve and confirm the proposed grant of 492,000 RSUs to Ms. Wang Xi pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
7.	To approve and confirm the proposed grant of 492,000 RSUs to Mr. Wang Feng pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
8.	To approve and confirm the proposed grant of 306,000 RSUs to Ms. Ma Yan pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
9.	To approve and confirm the proposed grant of 165,000 RSUs to Ms. Chen Yanqiong pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
10.	To approve and confirm the proposed grant of 129,000 RSUs to Mr. Yu Qingzhu pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
11.	To approve and confirm the proposed grant of 63,000 RSUs to Ms. Chen Qianjie pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
12.	To approve and confirm the proposed grant of 96,000 RSUs to Ms. Cong Yuehua pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
13.	To approve and confirm the proposed grant of 225,000 RSUs to Mr. Peng Shaoping pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
14.	To approve and confirm the proposed grant of 78,000 RSUs to Mr. Zhang Rong pursuant to the 2021 RSU Scheme.	313,150,938 99.188503%	2,562,000 0.811497%
15.	To authorize any one or more of the Directors to do all such acts and things and execute all such documents which he/they consider necessary, desirable or expedient for the purpose of, or in connection with, the implementation of and giving effect to the grant of RSUs and the transactions contemplated thereunder, including but not limited to the allotment and issue of the shares of the Company pursuant to the 2021 RSU Scheme.	298,911,138 94.678140%	16,801,800 5.321860%

As more than 50% of the votes attaching to the Shares held by the Shareholders present and voting in person or by proxy at the EGM were cast in favour of each of the Resolutions, the Resolutions were duly passed as the ordinary resolutions.

As at the date of the EGM, the total number of Shares in issue was 2,619,578,618 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the Resolutions at the EGM except for Resolution numbered 6 in relation to the proposed grant of RSUs to Ms. Wang Xi.

Mr. Ren Jinsheng (being the spouse of Ms. Wang Xi, who is a Connected Grantee under the 2021 RSU Scheme) and his associates hold a total of 2,037,903,965 Shares as at the date of the EGM, representing approximately 77.80% of the total issued share capital of the Company, were required to and did abstain from voting on the Resolution numbered 6 in relation to the proposed grant of RSUs to Ms. Wang Xi. Accordingly, the total number of Shares entitling the holders to attend and vote for or against the Resolution numbered 6 in relation to the proposed grant of RSUs to Ms. Wang Xi was 581,674,653 Shares.

Save as disclosed above, there were no Shares entitling the holder to attend and abstain from voting in favour of the Resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules. Saved as disclosed above, no Shareholder was required under the Listing Rules to abstain from voting on the Resolutions proposed at the EGM, and none of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the Resolutions proposed at the EGM.

Computershare Hong Kong Investor Services Limited, the share registrar of the Company in Hong Kong, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

By order of the Board of
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, November 1, 2021

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.